Common Questions

IBD-PSC is the overlap of inflammatory bowel disease (most often ulcerative colitis, sometimes Crohn's colitis) with primary sclerosing cholangitis (PSC), a chronic disease that scars the bile ducts. Most people with PSC also have IBD, and the combination behaves differently from IBD alone.

They frequently occur together: roughly two-thirds of people with PSC also have IBD, while PSC develops in only a small minority of people with ulcerative colitis. The colitis of IBD-PSC tends to be extensive but mild and most active on the right side. Rectal sparing and backwash ileitis are common in some studies and uncommon in others.

IBD-PSC carries a substantially higher risk of colorectal cancer than IBD without PSC. Guidelines recommend annual surveillance colonoscopy starting at the time of PSC diagnosis. PSC also raises the risk of bile-duct cancer (cholangiocarcinoma), which is monitored separately.

Not everyone does, but PSC can slowly progress to advanced liver disease over years, and liver transplantation is the most effective treatment for end-stage PSC. Many people live for a long time with PSC before transplant is considered, and care is shared with a hepatologist.

Yes. People with IBD-PSC who need surgery for ulcerative colitis can undergo ileal pouch-anal anastomosis (IPAA). Pouch outcomes are generally acceptable, though chronic pouchitis is more common in PSC. Timing relative to liver disease and transplant is individualized by the surgical and liver teams.

Primary sclerosing cholangitis (PSC) is a chronic liver disease in which the bile ducts inside and outside the liver become inflamed and scarred, narrowing them and slowing bile flow. Over years this can progress to liver damage. PSC is strongly linked to inflammatory bowel disease, raises the risk of bile-duct and colorectal cancer, and is followed by a hepatologist; advanced PSC liver disease may ultimately need a liver transplant.

Many people with early PSC have no symptoms and are picked up through routine liver blood tests. When symptoms occur, they can include fatigue, itching (pruritus), yellowing of the skin or eyes (jaundice), and episodes of fever or abdominal pain from bile-duct infection (cholangitis).

PSC is usually diagnosed with a combination of abnormal liver blood tests (particularly alkaline phosphatase) and imaging of the bile ducts, most often MRCP (a specialized MRI of the bile ducts), showing the characteristic narrowing and beading pattern. A liver biopsy is not always needed but can help in uncertain cases.

ERCP (endoscopic retrograde cholangiopancreatography) is a procedure that directly visualizes and can treat the bile ducts, used selectively in PSC. For example to dilate a dominant stricture or investigate a sudden change in liver tests. Rather than as a routine diagnostic tool, since MRCP is generally preferred for imaging alone.

A dominant stricture is a particularly narrow segment of bile duct that can cause more significant blockage, jaundice, or infection than the more diffuse narrowing typical of PSC. It sometimes needs endoscopic treatment (such as balloon dilation via ERCP) and always warrants evaluation to exclude bile-duct cancer.

Itching from PSC is treated with medications that bind bile acids or affect bile-acid signaling, and for some patients other agents are used when first-line treatments aren't enough. It can be one of the more disruptive symptoms of PSC even before major liver damage develops, so it's worth reporting rather than tolerating.

IBD-PSC colitis tends to involve the whole colon (pancolitis) even when symptoms are mild, often spares the rectum, and can include backwash ileitis (inflammation extending into the last part of the small bowel), a combination that can look unusual on colonoscopy compared with ulcerative colitis alone.

Annual colonoscopy with biopsies throughout the colon, starting from the time of PSC diagnosis (rather than waiting the 8-10 years typically used for ulcerative colitis alone), is the standard recommendation, since the elevated cancer risk in IBD-PSC begins earlier.

Monitoring typically includes periodic imaging (often annual MRI/MRCP) and sometimes a tumor marker blood test (CA 19-9), watching for a new dominant stricture or rapid change in liver tests, which can be signs of cancer and prompt further evaluation.

Yes, generally. Biologic and immunosuppressive therapy for IBD is used in IBD-PSC much as it would be otherwise, with coordination between gastroenterology and hepatology to account for liver function and any additional risk from combined therapy.

Alkaline phosphatase (ALP) and other liver blood tests are checked periodically to track PSC activity. A falling or normalized ALP over time is generally viewed as a favorable sign, while a rising trend can prompt further imaging or evaluation.

PSC can recur in the transplanted liver in a meaningful proportion of patients over the years following transplant, so post-transplant monitoring continues, and recurrent PSC is one of the reasons some patients eventually need a second transplant.

Transplant listing is based on a combination of liver function scores (such as MELD), symptoms like refractory itching or recurrent cholangitis, and quality of life. It's a decision made together with a transplant hepatology team, and many people are followed for years before listing becomes appropriate.

No specific diet reverses PSC, but general liver-healthy habits. Limiting alcohol, maintaining a healthy weight, and managing IBD-related nutrition needs. Support overall health, and your hepatology and gastroenterology teams can help tailor guidance to your combined condition.

The course varies widely. Some people have a slowly progressive disease over decades, while others progress more quickly to advanced liver disease. Regular follow-up with both a hepatologist and gastroenterologist, along with cancer surveillance, is the main way outcomes are optimized regardless of the pace of disease.